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SUPERIOR COURT
CIVIL ACTION
Docket No. CV-17-

STATE OF MAINE
KENNEBEC, ss.

STATE OF MAINE,

)

)

Plaintiff

)

)

v.
BOEHRINGERINGELHEIM
PHARMACEUTICALS, INC.

)
)
)
)

COMPLAINT
(Injunctive Relief Requested)

)
Defendant

)
INTRODUCTION

1.

Plaintiff State of Maine brings this action, by and through its Attorney General,

against Defendant, Boehringer Ingelheim Pharmaceuticals, Inc., for violating 5 M.R.S. § 207 of
the Maine Unfair Trade Practices Act (the “UTPA,” 5 M.R.S. §§ 205-A - 214).
PARTIES
2.

Plaintiff, State of Maine, brings this action by and through its Attorney General,

Janet T. Mills, in the public interest, pursuant to authority granted her by 5 M.R.S. § 209.
3.

Defendant Boehringer Ingelheim Pharmaceuticals, Inc. (“BIPI”) is a Delaware

corporation with its principal place of business at 900 Ridgebury Road, in Ridgefield,
Connecticut 06877. At all relevant times, BIPI engaged in trade or commerce in the State of
Maine by marketing, promoting, and selling the prescription drugs Micardis, Aggrenox,
Atrovent, and Combivent.
JURISDICTION AND VENUE
4.

This Court has subject matter jurisdiction pursuant to 4 M.R.S. § 105 and 5

M.R.S. § 209. This Court has jurisdiction over BIPI pursuant to 14 M.R.S. § 704-A(2) because

BIPA has transacted business within the State of Maine at all times relevant to this Complaint.
5.

Venue for this action is properly laid in Kennebec County, pursuant to 5 M.R.S.

§209.
ALLEGATIONS
Aggrenox
6.

Aggrenox (a combination of aspirin and dipyridamole) is an antiplatelet drug that

was approved by the U.S. Food and Drug Administration (“FDA”) in 1999 to reduce the risk of
secondary stroke in patients who have had a transient ischemic attack (“TIA”), which is
sometimes referred to as a “mini stroke,” or stroke due to a blood clot.
7.

Aggrenox’s main competitor was Plavix, which the FDA approved in 1997.

8.

Plavix had an indication to reduce the risk of secondary stroke following a TIA or

stroke due to a blood clot; however, it also had indications to treat a broader range of secondary
clot-related events, including myocardial infarction and peripheral artery disease (“PAD”), which
is also referred to as peripheral vascular disease (“PVD”).
9.

BIPI represented that Aggrenox was superior to Plavix and Plavix/aspirin

combinations when, in fact, BIPI lacked competent and reliable scientific evidence to
substantiate its claims.
10.

BIPI also represented that Aggrenox was effective “below the neck” to treat

myocardial infarction (heart attack), congestive heart failure, and PAD/PVD when, in fact, BIPI
lacked competent and reliable scientific evidence to substantiate its claims.
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Micardis
11.

Micardis (telmisartan) belongs to a class of drugs called angiotensin receptor

blockers (“ARBs”) and is indicated to treat hypertension (high blood pressure) and to reduce
cardiovascular risk in patients unable to take angiotensin-converting-enzyme (“ACE”) inhibitors.
12.

The FDA approved Micardis in 1998 as the fourth ARB on the market.

13.

At that time, the hypertension market was already dominated by Diovan, Cozaar,

and Avapro.
14.

Initial sales for Micardis were poor, in part, because BIPI had no comparative

data proving Micardis was superior to any of the existing hypertension drugs.
15.

Both Cozaar and Avapro received additional indications for treatment of renal

nephropathy among diabetics, which distinguished them from other hypertension drugs,
including Micardis.
16.

Similarly, there was data suggesting that Cozaar was effective in the prevention of

secondary myocardial infarction.
17.

To increase sales, BIPI created marketing messages that lacked substantiation in

an effort to distinguish Micardis from the competition.
18.

BIPI represented that Micardis best protects consumers from the “early morning

risk” of strokes or cardiac events due to rising blood pressure for patients at the end of a dosing
interval for hypertension drugs when, in fact, BIPI lacked competent and reliable scientific
evidence to substantiate its claim.
19.

BIPI also represented that Micardis could treat the constellation of symptoms

popularly known as “Metabolic Syndrome,” protected the kidneys, and prevented heart attacks
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and strokes when, in fact, BIPI lacked competent and reliable scientific evidence to substantiate
its claims.
Atrovent and Combivent
20.

Both Atrovent (ipratropium bromide) and Combivent (ipratropium bromide and

albuterol) are bronchodilators indicated to treat bronchospasms (airway narrowing) associated
with chronic obstructive pulmonary disease (“COPD”) and contain albuterol plus a drug
belonging to a class called anticholinergics.
21.

Atrovent is approved as a first line treatment; however, Combivent is only

approved for use when a person continues to have evidence of bronchospasm when using a
regular aerosol bronchodilator.
22.

BIPI represented Combivent could be used as a first line treatment for

bronchospasms associated with COPD when, in fact, Combivent is not indicated as a first line
treatment and BIPI lacked competent and reliable scientific evidence to substantiate its claim.
23.

BIPI also represented that both Atrovent and Combivent could be used at doses

that exceed the maximum dosage recommendation in the product labeling when, in fact, BIPI
lacked competent and reliable scientific evidence to substantiate its claim.
24.

BIPI iurther represented that anticholinergics were essential for treatment of

COPD when, in fact, BIPI lacked competent and reliable scientific evidence to substantiate its
claim.
VIOLATIONS OF MAINE UNFAIR TRADE PRACTICES ACT
5 M.R.S. § 207
25.

Plaintiff realleges and incorporates by reference herein each and every allegation

contained in the preceding Paragraphs 1 through 24 of this Complaint.
26.

BIPI, in the course of marketing, promoting, and selling the prescription drugs
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Micardis, Aggrenox, Atrovent, and Combivent, has engaged in unfair and deceptive practices
through its omissions and misrepresentations about the prescription drugs Micardis, Aggrenox,
Atrovent, and Combivent, in violation of 5 M.R.S, § 207.
27.

BIPI, in the course of marketing, promoting, and selling the prescription drugs

Micardis, Aggrenox, Atrovent, and Combivent, has engaged in unfair and deceptive practices
through its representations that the prescription drugs Micardis, Aggrenox, Atrovent, and
Combivent have sponsorship, approval, characteristics, ingredients, uses, benefits, quantities, or
qualities that they do not have, in violation of 5 M.R.S. § 207.
PRAYER FOR RELIEF
WHEREFORE, Plaintiff respectfully requests that this Court:
A.

Declare that BIPI has violated 5 M.R.S. § 207 through its omissions and

misrepresentations about the prescription drugs Micardis, Aggrenox, Atrovent and Combivent,
and through its representations that these drugs have sponsorship, approval, characteristics,
ingredients, uses, benefits, quantities, or qualities that they do not have;
B.

Pursuant to 5 M.R.S. § 209, permanently enjoin and restrain BIPI, its agents,

employees, and all other persons and entities, corporate or otherwise, in active concert or
participation with any of them, from engaging in any unfair and deceptive act or practice that
violates 5 M.R.S. § 207 in the marketing, promotion, and sale of the prescription drugs Micardis,
Aggrenox, Atrovent, and Combivent;
C.

Pursuant to 5 M.R.S. § 209, order BIPI to pay civil penalties of up to $10,000 for

each and every intentional violation of 5 M.R.S. § 207;
D.

Pursuant to 5 M.R.S. § 209 and 14 M.R.S. § 1522(1)(A), order BIPI to pay all

costs for the prosecution and investigation of this action; and
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E.

Grant Plaintiff such other and further relief as the Court deems equitable and

proper.

Dated: December 20, 2017

Respectfully submitted,
JANET T. MILLS
ATTORNEY GENERAL

Carolyn A. SJlsby, ME Bar No, 303
Linda J. Conti, ME Bar No. 3638
Assistant Attorneys General
Office of the Attorney General
6 State House Station
Augusta, ME 04333-0006
(207)626-8800
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